Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss ...

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord ...

The addition of SI joint fusion products complements Nevro’s SCS offerings, as they address different types of chronic pain ... new product launches, such as HFX iQ with AdaptivAI, strengthening ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza ® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...